The degradation of ErbB2 and EGFR that play direct roles in the progression of breast and lung cancers are degraded by hTid-1 via the proteasomal pathway which is an important indicator as to why hTid-1 can act as a potential molecule of interest in the future to treat cancers. Here, ERBB2 is linked to lung carcinoma.